Neurocrine Biosciences vs Regeneron Pharmaceuticals
Neurocrine Biosciences (NBIX) and Regeneron Pharmaceuticals (REGN) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $15.2B
- Last close
- $150.57
- 12 months
- +8.3%
- Market value
- $95.2B
- Last close
- $920.69
- 12 months
- +24.9%
At a glance
- The biggest part of Regeneron Pharmaceuticals's revenue is Collaboration revenue, 51% of the total in its last annual report.
- By market value, Regeneron Pharmaceuticals ($95.2B) is about 6.2 times Neurocrine Biosciences ($15.2B).
- Over the last 12 months Neurocrine Biosciences's share price moved +8.3% and Regeneron Pharmaceuticals's +24.9%; against the S&P 500 that is +2.6 points and +19.2 points.
- In their last fiscal years Neurocrine Biosciences kept 16.7% of revenue as net income and Regeneron Pharmaceuticals 31.4%.
- In the last 90 days insiders reported 0 open-market purchases at Neurocrine Biosciences and 0 at Regeneron Pharmaceuticals; members of Congress disclosed 0 trades in Neurocrine Biosciences and 0 in Regeneron Pharmaceuticals.
- Next results: Neurocrine Biosciences Feb 9, 2027, Regeneron Pharmaceuticals Jan 28, 2027.
How each one makes money: Neurocrine Biosciences revenue · Regeneron Pharmaceuticals revenue
Share prices on one chart
Neurocrine Biosciences and Regeneron Pharmaceuticals, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Neurocrine Biosciences NBIXNASDAQ · Biotechnology | Regeneron Pharmaceuticals REGNNASDAQ · Biotechnology | |
|---|---|---|
| Size and profitability | ||
| Market value | $15.2B | $95.2B |
| Revenue, last fiscal year | $2.86B | $14.3B |
| Net income, last fiscal year | $479M | $4.5B |
| Net marginNet income as a share of revenue | 16.7% | 31.4% |
| Free cash flow | $749M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Compare with another company
Regeneron Pharmaceuticals against
Common questions
How is Neurocrine Biosciences different from Regeneron Pharmaceuticals?
Neurocrine Biosciences (NBIX) is in Biotechnology on NASDAQ, with $2.86B of revenue in its last fiscal year and a net margin of 16.7%. Regeneron Pharmaceuticals (REGN) is in Biotechnology on NASDAQ, with $14.3B of revenue in its last fiscal year and a net margin of 31.4%. The biggest part of Regeneron Pharmaceuticals's revenue is Collaboration revenue, 51% of the total in its last annual report. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Neurocrine Biosciences and Regeneron Pharmaceuticals compare in size?
Regeneron Pharmaceuticals has the larger market value: Neurocrine Biosciences $15.2B and Regeneron Pharmaceuticals $95.2B, at the last close.
Whose share price rose more over the last 12 months, NBIX or REGN?
Over the last 12 months Neurocrine Biosciences moved +8.3% and Regeneron Pharmaceuticals +24.9%. Past price moves say nothing about the future.
Which has had more insider buying, Neurocrine Biosciences or Regeneron Pharmaceuticals?
Since 2006, Regeneron Pharmaceuticals insiders reported 551 open-market purchases against 106 for Neurocrine Biosciences. These are counts of what was filed, not a view on either stock.
Do members of Congress trade NBIX or REGN?
In the last 12 months, members of Congress disclosed 0 trades in Neurocrine Biosciences (NBIX) and 4 in Regeneron Pharmaceuticals (REGN).
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Neurocrine Biosciences pageRegeneron Pharmaceuticals pageRare insider trades this weekAll comparisons
https://oqro.io/compare/nbix-vs-regn







